EC Number   |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
|---|
    2.4.1.132 | Carcinoma |
33084111 |
ALG3 contributes to the malignant properties of OSCC cells by regulating CDK-Cyclin pathway. |
ongoing research
therapeutic application
unassigned |
4
2
0 |
| 2.4.1.132 | Congenital Disorders of Glycosylation |
12684507 |
A new type of congenital disorders of glycosylation (CDG-Ii) provides new insights into the early steps of dolichol-linked oligosaccharide biosynthesis. |
causal interaction
unassigned |
4
0 |
| 2.4.1.132 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
12684507 |
A new type of congenital disorders of glycosylation (CDG-Ii) provides new insights into the early steps of dolichol-linked oligosaccharide biosynthesis. |
causal interaction
unassigned |
4
0 |
| 2.4.1.132 | Neoplasms |
31899049 |
ALG3 contributes to the malignancy of non-small cell lung cancer and is negatively regulated by MiR-98-5p. |
causal interaction
unassigned |
3
0 |
| 2.4.1.132 | Squamous Cell Carcinoma of Head and Neck |
33084111 |
ALG3 contributes to the malignant properties of OSCC cells by regulating CDK-Cyclin pathway. |
ongoing research
therapeutic application
unassigned |
4
2
0 |
